Top

Tag: biotech


Mergers and Acquisitions

Thermo Fisher Scientific Announces Founding Sponsorship of Momentum Labs

February 6, 2023

Via: Biopharm International

Thermo Fisher Scientific recently announced that it had become a founding sponsor of Momentum Labs, a collaborative laboratory and office space to be located in Alachua, Fla. The venture, spearheaded by Gainesville real estate development firm Concept Companies, is designed […]


Biotech, Industry

UK biotech sees worst funding downturn since 2012

January 27, 2023

Via: Pharmaphorum

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. But with difficult public markets and low investor appetite, new launches were almost unseen in 2022, with public markets contributing […]


Biotech, Industry

Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’

January 25, 2023

Via: Biopharma Dive

Goulburn, Dar and Li believe a shift is underway in biotech. The three friends, who have helped build new companies with their respective firms for about a decade, are convinced the search for new drugs is becoming increasingly digitized. Artificial […]


Biotech, Industry

5 questions facing emerging biotech in 2023

January 10, 2023

Via: Biopharma Dive

Here are five top questions facing emerging biotech companies this year: Will the IPO market open back up? The big question facing investors is whether the biotech industry will see the kind of boom it experienced in 2020 and 2021. […]


Biotech, Industry

It’s time for more tech and biotech innovation in 2023

January 5, 2023

Via: Pharmaphorum

For biotech to achieve our societal goals, we need to build up the foundational systems that support modern science. Government investment will be critical. Technological resources will also be instrumental — from overcoming current technical skills gaps to modernising how […]


Biotech, Industry, Pharma

European Health Data Space (EHDS) update: what this means for pharmaceutical and biotech

January 4, 2023

Via: Pharmaphorum

The intention is to streamline the process for patients wishing to access their medical records via electronic health record systems (“EHR systems”) and to facilitate the ability for researchers, innovators, and policy makers to use the data in a trusted […]


Clinical Trials, Research and Development

10 clinical trials to watch in the first half of 2023

January 3, 2023

Via: Biopharma Dive

The biotechnology industry begins 2023 at a crossroads. In many ways, the sector is coming off of one of its toughest years in recent memory. Initial public offerings ground to a halt. A widely followed biotech stock index plunged nearly […]


Biotech, Industry

After $250M Roche buyout, a startup plans a second strike with fresh funding

November 15, 2022

Via: Biopharma Dive

Two months ago, biotechnology startup Good Therapeutics struck it big. A cancer immunotherapy the company was working on drew such interest from Roche that the Swiss pharmaceutical giant paid $250 million, far more than the $30 million the startup had […]


Mergers and Acquisitions

Nordic Nanovector to merge with APIM after Betalutin fail

November 10, 2022

Via: Pharmaphorum

The merger will create a clinical-stage cancer-focused biotech with funding that will last into 2024 and pipeline headed by ATX-101, a peptide-targeting PCNA being developed by APIM in clinical trials for platinum-sensitive ovarian cancer and sarcoma. Nordic Nanovector was hit […]


Biotech, Industry

Prime Medicine raises $175M in one of the year’s largest biotech IPOs

October 20, 2022

Via: Biopharma Dive

Plunging stock prices shook the biotech sector this year. Young companies attempting to go public found little appetite for the sky-high valuations that were common in 2020 and 2021’s bull run of IPOs. Some investors described that period as resulting […]


News

A Versant-backed biotech emerges to take on ‘overlooked’ cancer targets

October 6, 2022

Via: Biopharma Dive

Scientists knew the gene all too well. Decades of research had shown that mutated versions of it were behind a variety of cancers. But designing a medicine that could block the effects of this gene, called KRAS, proved exceptionally challenging, […]


Mergers and Acquisitions

AstraZeneca to acquire gene editing biotech LogicBio

October 3, 2022

Via: Biopharma Dive

AstraZeneca’s rare disease unit Alexion will acquire gene editing specialist LogicBio Therapeutics in a small buyout deal, the companies announced Monday. Under the terms of the agreement, Alexion will acquire all of LogicBio’s outstanding shares for $2.07 each, representing a […]


Biotech, Industry

Prime Medicine becomes the next high-profile biotech to test the IPO waters

September 26, 2022

Via: Biopharma Dive

Prime’s filing represents a key test for biotech initial public offerings, which are showing some early signs of life after a prolonged slowdown. Twelve days ago, autoimmune drug developer Third Harmonic Bio provided the sector with a lift. By raising […]


Biotech, Industry

Biotechnology Gets $2 Billion Boost from the White House

September 15, 2022

Via: GEN

This week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]


Mergers and Acquisitions

Aptar Pharma Acquires Metaphase Design Group

September 6, 2022

Via: Contract Pharma

Aptar Pharma, a leader in drug delivery and active material science solutions and services, has acquired Metaphase Design Group Inc., a leader in applying the science of human factors engineering and ergonomics to product design. The acquisition expands Aptar Pharma’s […]


Mergers and Acquisitions

Novo Nordisk steps up sickle cell push with $1.1bn Forma buy

September 2, 2022

Via: Pharmaphorum

The $20-per-share agreement was a premium of 92% over Forma’s closing share price yesterday, but its stock leaped after the deal was announced from $13.40 to just under the deal price. The biotech went public via a $278 million IPO […]


Manufacturing, Research and Development

Streamlining Bulk mAb Manufacturing

September 2, 2022

Via: Biopharm International

With biosimilars entering the market, and more expected to reach the market in the near future, the need for good manufacturing practice (GMP) compliance is growing more crucial for bulk monoclonal antibody (mAb) manufacturing. Beyond innovator biologics, biosimilars are expected […]


Cell and Gene Therapy, Industry

Sangamo presses ahead with Fabry disease gene therapy

September 1, 2022

Via: Biopharma Dive

Sangamo Therapeutics is continuing to enroll and treat patients with a rare genetic condition called Fabry disease in an early clinical trial of a gene therapy it is developing, announcing Tuesday updated results from the first 11 study participants. Data […]


News

Ori Biotech Expands Expertise and Personnel, Adds New Facilities

September 1, 2022

Via: Contract Pharma

Ori Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, has shared details of its strategic expansion plan following its $100 million Series B funding round in January 2022, including adding key expertise and personnel and new […]


Cell and Gene Therapy, Industry

Beam details reasons for FDA hold on base editing cancer therapy

August 31, 2022

Via: Biopharma Dive

FDA officials are proceeding with caution as the gene editing field advances. In another recent example, the agency had issued a partial clinical hold to Editas Medicine before this July allowing that company to proceed with testing of a sickle […]